



### ARDS: A high-mortality syndrome with no approved disease-modifying therapies



### Phase 3 Study Design: Intent to treat population of 104 patients on IMV


ITT Population (IMV with or without ECMO/Organ Support)



**Key Inclusion Criteria**

- Men and women >18 years old
- Positive COVID-19 test
- Negative pregnancy test
- IMV


**Safety Population (with or without IMV)**




**Key Exclusion Criteria**

- Pregnant or breastfeeding women
- Progression to death within 48-72h is imminent/inevitable
- Active participation in immunomodulator trials
- Treatment with immunosuppressant drugs that are not part of SOC
- Meaningful clinical improvement prior to administration


### Paridiprubart: A highly selective TLR4 inhibition designed for acute critical-care



### Phase 3 Baseline Characteristics: Intent to treat population of 104 patients on IMV



### Phase 3 Study Results: Key Primary and Secondary Endpoints



\* Estimated risk of mortality using multivariate logistic regression derived risk differences (95% confidence interval)